HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hemp Industry Appeals To National Governments Over CBD Narcotic Classification

Executive Summary

Hemp industry groups in France and Germany are separately appealing to their national governments to intervene in the European Commission's attempt to classify CBD as a narcotic rather than novel food.

You may also be interested in...



UN Vote On Cannabis Controls Could Be Crucial To CBD’s Future In EU

Legal experts say the EU already prohibits cosmetic use of CBD sourced from hemp flowers, and it now appears that food supplement use could be held to the same standard. The World Health Organization has recommended changes to the half-century-old international treaty governing narcotic controls, which could help to resolve the situation, but there are reports of UN pushback.

EU CBD Market Under Threat With Narcotic Classification Favored

Leaning towards classifying CBD as a narcotic, the European Commission could dash hopes of a regulated EU market for dietary supplements containing the cannabinoid. 

Euro Q1 Consumer Health Earnings Preview: Reckitt, Sanofi, Haleon, Bayer

Major Europe-based consumer health players Reckitt, Sanofi, Haleon and Bayer feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q1 2024 results over the coming weeks.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150390

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel